Disease relevance of Taractan

• Catalepticlike state and moderate to marked hypothermia induced by all doses of chlorprothixene, 10 and 15 mg/kg perphenazine, and 20 mg/kg methadone were not reversed by mescaline [1].
• Two trials of chlorprothixene were carried out, mainly on patients with moderate to severe post-herpetic neuralgia [2].
• Polyneuropathy caused by chlorprothixene [3].
• Contact dermatitis to chlorprothixene [4].
• Acute oliguria associated with chlorprothixene overdosage [5].

Psychiatry related information on Taractan

• Significantly higher rates of tiredness, sedation and hypersomnia were found on bromazepam and chlorprothixene compared to placebo [6].
• Antidepressant combination therapy of endogenous depressions with benzodiazepines or neuroleptics--a study comparing adjuvant treatment with oxazolam versus chlorprothixene [7].

High impact information on Taractan

• Five acidic calix[4]arenes with carboxylic or sulfonic groups at either the upper or lower rim of the cavity and one resorc[4]arene were investigated to separate three thioxanthenes (flupentixol, clopenthixol, chlorprothixene) and a dibenz[b,e]oxepin derivative (doxepin) with cis-/trans-isomerism by nonaqueous capillary electrophoresis (NACE) [8].
• Chlorprothixene-induced systemic lupus erythematosus [9].
• Chlorprothixene (taractan) in post-herpetic neuralgia and other severe chronic pains [2].
• The objective of this study was the construction of a pharmacokinetic-pharmacodynamic model to describe the effects of chlorprothixene on prolactin secretion and the time-dependent alterations in the concentration-effect relationship due to tolerance development [10].
• Bromazepam was compared with placebo and with chlorprothixene in a randomized, double-blind group-comparative multicenter trial in general practice [6].

Chemical compound and disease context of Taractan

• The phenothiazines (chlorpromazine, chlorprothixene, and triflupromazine) inhibited Acanthamoeba growth by 70-90% at 5 and 10 micrograms/ml, but some of these compounds were toxic for rat glioma cells at 10 micrograms/ml [11].
• The activity of the non-neuroleptic stereo-isomers of clopenthixol and chlorprothixene may lead to investigation in patients with peptic ulcer disease of this kind of agents [12].
• Desipramine, trimipramine, protriptyline, noxiptyline, promazine, trimeprazine, triflupromazine and chlorprothixene methoiodide eliminated the F'lac plasmid of Escherichia coli, while thiazinanum, toluidine blue, lidocaine and procaine were ineffective in this respect [13].
• There were more side effects with chlorprothixene/phenobarbital, in particular tachycardia and hyperexcitation [14].

Biological context of Taractan

• Penfluridol, chlorprothixene and haloperidol block fast axonal transport in an order of potency consistent with a mechanism related to inhibition of calmodulin [15].
• Tricyclic compounds in which the nitrogen in the middle ring was substituted with a carbon atom (amitryptyline and chlorprothixene) are most effective in causing cell death and in decreasing proline transport and delta pH (IC50 congruent to 5 microM), whereas depletion of cellular ATP requires a higher drug concentration (IC50 = 12 microM) [16].
• We enhanced the performance of the deconvolution method by directly generating initial estimates of one input rate for each sampling interval and compared the statistical properties of various input rate characteristics using data from a bioavailability study on four chlorprothixene preparations [17].
• On the pharmacokinetics of chlorprothixene in man [18].
• The individual and combined influences of pentobarbital and chlorprothixene on the early components of the cortical visual evoked potential (VEP) were examined in the C57BL/6 mouse [19].

Anatomical context of Taractan

• From urine and feces of dogs and urine of patients given chlorprothixene (CPT) per os, metabolites were extracted without or with enzymatic deconjugation and separated by repeated TLC [20].
• Seven chronic psychiatric patients developed signs of polyneuropathy mainly in the lower limbs after receiving chlorprothixene (500-1800 mg/d) from 3 to more than 24 months [3].
• Presence of chlorprothixene and its metabolites in breast milk [21].
• Chlorprothixene and chlorprothixene sulfoxide (CPT-SO) metabolite concentrations (mg/L) in body fluids as determined by spectrophotofluorometry were: blood, 0.10 and 0.60; bile, 3.9 and 7.0; urine, 0.4 and 3.4; and stomach contents, 340 mg and 25 mg total, respectively [22].

Associations of Taractan with other chemical compounds

• Concomitant administration of IMI and CPZ or IMI and CPX elevated the cytochrome P-450 level and accelerated IMI demethylation in in vitro study [23].
• Determination of chlorprothixene and its sulfoxide metabolite in plasma by high-performance liquid chromatography with ultraviolet and amperometric detection [24].
• A controlled study was conducted involving 40 endogenous depressive inpatients who were treated with maprotiline in combination with the benzodiazepine oxazolam or the neuroleptic chlorprothixene [7].
• Qualitative identification of chlorprothixene and CPT-SO was by thin layer and gas liquid chromatography and spectrophotofluorometry following alkaline permanganate oxidation [22].
• A reversed-phase HPLC method with UV detection at 252 nm is presented for the simultaneous determination of some tricyclic antidepressants (amitriptyline, imipramine) and neuroleptics (chlorprothixene, thioridazine) in their quaternary mixtures [25].

Gene context of Taractan

• The absolute and relative bioavailability of chlorprothixene (CAS 113-59-7, Truxal) was studied in eight healthy male volunteers with three different formulations: solution, suspension and coated tablet [26].

Analytical, diagnostic and therapeutic context of Taractan

• Prolactin and chlorprothixene serum concentrations were determined in eight healthy men for up to 72 h after the intravenous and oral administration of chlorprothixene [10].
• Hemoperfusion in severe chlorprothixene overdose [27].
• ELISA screening with GC-MS confirmation of the tranquilizer chlorprothixene administered in subtherapeutic doses to horses [28].
• However, a controlled double-blind study of haloperidol vs. chlorprothixene in schizophrenic patients found no significant differences [29].

References